Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.

This article has no abstract
Epistemonikos ID: 03b2403cb8e9f8b1208eae5df5fed3090769f067
First added on: Feb 19, 2025